anti-CCL-2 human monoclonal antibody CNTO 888

Definition / meaning of anti-CCL-2 human monoclonal antibody CNTO 888

A recombinant monoclonal antibody directed against human CC chemokine ligand 2 (CCL2) with potential antineoplastic activity. Anti-CLL2 human monoclonal antibody CNTO 888 binds to and inhibits CLL2, which may result in inhibition of angiogenesis and, so, tumor cell proliferation. Endothelium-derived CLL2 (monocyte chemoattractant protein; MCP1) is a member of the beta-chemokine family, can stimulate monocyte/macrophage migration and smooth muscle cell (SMC) proliferation, and plays a role in angiogenesis and tumor cell migration; CCL2 induction of angiogenesis may involve the upregulation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression which, in turn, induces vascular endothelial growth factor-A (VEGF-A) gene expression.

Listed under:

Find More About 'anti-CCL-2 human monoclonal antibody CNTO 888'

Source(s):

The Web site of the National Cancer Institute (http://www.cancer.gov/)

Leave a Comment

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.